<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MAGNESIUM SULFATE</span><br/>(mag-nes'i-um)<br/><span class="topboxtradename">Epsom Salt<br/></span><b>Classifications:</b> <span class="classification">gastrointestinal agent</span>; <span class="classification">saline cathartic</span>; <span class="classification">replacement agent</span>; <span class="classification">anticonvulsant</span><br/><b>Prototype: </b>Magnesium Hydroxide<br/><b>Pregnancy Category: </b>A<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.8 mEq/mL, 1 mEq/mL, 4 mEq/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>
<i>Orally:</i> Acts as a laxative by osmotic retention of fluid, which distends colon, increases water content of feces, and causes mechanical
         stimulation of bowel activity. <i>Parenterally:</i> Acts as a CNS depressant and also as a depressant of smooth, skeletal, and cardiac muscle function. Anticonvulsant properties
         thought to be produced by CNS depression, principally by decreasing the amount of acetylcholine liberated from motor nerve
         terminals, thus producing peripheral neuromuscular blockade.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective parenterally as a CNS depressant, smooth muscle relaxant and anticonvulsant in labor and delivery, and cardiac disorders.
         It is a laxative when taken orally.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Orally to relieve acute constipation and to evacuate bowel in preparation for x-ray of intestines. Parenterally to control
         seizures in toxemia of pregnancy, epilepsy, and acute nephritis and for prophylaxis and treatment of hypomagnesemia. Topically
         to reduce edema, inflammation, and itching.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>To inhibit premature labor (tocolytic action) and as adjunct in hyperalimentation.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Myocardial damage; heart block; cardiac arrest except for certain arrhythmias; IV administration during the 2 h preceding
         delivery; PO use in patients with abdominal pain, nausea, vomiting, fecal impaction, or intestinal irritation, obstruction,
         or perforation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired kidney function; digitalized patients; concomitant use of other CNS depressants; neuromuscular blocking agents, or
         cardiac glycosides; pregnancy (category A), lactation, children.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Laxative</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1015 g once/d<br/><br/><span class="indicationtitle">Preeclampsia, Eclampsia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM/IV</span> 4 g in 250 mL D5W infused slowly, followed by 45 g IM in alternate buttocks q4h<br/><br/><span class="indicationtitle">Hypomagnesemia Seizures</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM/IV</span>
<i>Mild,</i> 1 g q6h for 4 doses; <i>Severe,</i> 250 mg/kg infused over 4 h<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 20100 mg/kg q46h prn<br/><br/><span class="indicationtitle">Total Parenteral Nutrition</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.53 g/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give in the morning or mid-afternoon in a glass of water for laxative action. Disguise bitter, salty taste by chilling or
            flavoring with lemon or orange juice.
         </li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Give deep using the 50% concentration for adults and the 20% concentration for children.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>
                     					Note: Verify correct IV concentration and rate of infusion for administration to infants, children with physician.
                     				
                  </li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct/</span><span class="methodtype">IV Infusion:</span> Give solutions with concentrations of <img src="../images/special/lesserorequal.gif"/>20% undiluted.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give at a rate of 150 mg over at least 1 min. Note: 20% solution contains 200 mg/mL, 10% solution contains 100 mg/mL.  <span class="methodtype">IV Infusion:</span> Give required dose over 4 h. Do not exceed the direct rate.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>10% fat emulsion;</b>
<b>amphotericin B,</b>
<b>calcium gluceptate,</b>
<b>clindamycin,</b>
<b>cyclosporine,</b>
<b>dobutamine,</b>
<b>polymyxin B sulfate,</b>
<b>procaine,</b>
<b>sodium bicarbonate.</b>
<span class="incompattype">Y-site:</span>
<b>Amiodarone, amphotericin B, cholesteryl,</b>
<b>cefepime.</b>
</p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Flushing, sweating, extreme thirst, sedation, confusion, depressed reflexes or no reflexes, muscle weakness, <span class="speceff-life">flaccid paralysis</span>, hypothermia. <span class="typehead">CV:</span> Hypotension, depressed cardiac function, <span class="speceff-life">complete heart block, circulatory collapse</span>. <span class="typehead">Respiratory:</span>
<span class="speceff-life">Respiratory paralysis</span>. <span class="typehead">Metabolic:</span> Hypermagnesemia, hypocalcemia, dehydration, electrolyte imbalance including hypocalcemia with repeated laxative use. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">neuromuscular blocking agents</span> add to respiratory depression and apnea. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 12 h PO; 1 h IM. <span class="typehead">Duration:</span> 30 min IV; 34 h PO. <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. <span class="typehead">Elimination:</span> Eliminated in kidneys. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Observe constantly when given IV. Check BP and pulse q1015 min or more often if indicated.</li>
<li>Lab tests: Monitor plasma magnesium levels in patients receiving drug parenterally (normal: 1.83.0 mEq/L). Plasma levels
            in excess of 4 mEq/L are reflected in depressed deep tendon reflexes and other symptoms of magnesium intoxication (see <small>ADVERSE EFFECTS</small>). Cardiac arrest occurs at levels in excess of 25 mEq/L. Monitor calcium and phosphorus levels also.
         </li>
<li>Early indicators of magnesium toxicity (hypermagnesemia) include cathartic effect, profound thirst, feeling of warmth, sedation,
            confusion, depressed deep tendon reflexes, and muscle weakness.
         </li>
<li>Monitor respiratory rate closely. Report immediately if rate falls below 12.</li>
<li>Test patellar reflex before each repeated parenteral dose. Depression or absence of reflexes is a useful index of early magnesium
            intoxication.
         </li>
<li>Check urinary output, especially in patients with impaired kidney function. Therapy is generally not continued if urinary
            output is less than 100 mL during the 4 h preceding each dose.
         </li>
<li>Observe newborns of mothers who received parenteral magnesium sulfate within a few hours of delivery for signs of toxicity,
            including respiratory and neuromuscular depression.
         </li>
<li>Observe patients receiving drug for hypomagnesemia for improvement in these signs of deficiency: Irritability, choreiform
            movements, tremors, tetany, twitching, muscle cramps, tachycardia, hypertension, psychotic behavior.
         </li>
<li>Have calcium gluconate readily available in case of magnesium sulfate toxicity.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Drink sufficient water during the day when drug is administered orally to prevent net loss of body water.</li>
<li>Recommended daily allowances of magnesium are obtained in a normal diet. Rich sources are whole-grain cereals, legumes, nuts,
            meats, seafood, milk, most green leafy vegetables, and bananas.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>